Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity
What this study shows
In mice, chronic rapamycin also disrupts mTORC2, causing insulin resistance; lifespan extension can be uncoupled from this side effect.
At a glance
| Evidence type | A Animal model Marked A because it is an animal intervention or observation study measuring an organismal outcome (model: Mouse (in vivo glucose and insulin tolerance)); the code names the system studied -- animal work can be rigorous and still not be human data. |
| Study type | 4 - Animal Study |
| Model system | Mouse (in vivo glucose and insulin tolerance) |
| Journal | Science |
| Year | 2012 |
| Peer reviewed | Yes |
| Record last updated | 2026-07-29 |
| Source | DOI 10.1126/science.1215135 · PMID 22461615 · Free full text (PMC3324089) |
Extracted findings
| Intervention | Rapamycin (chronic) |
| Target | mTORC1 vs mTORC2 |
| Model | Mouse |
| Effect | In mice, chronic rapamycin causes insulin resistance via disruption of mTORC2, uncoupled from its longevity effect |
In the Atlas
Related topics
Open questions that cite this study
- Cited as supporting evidence for the open question Sensor-selective geroprotection without the metabolic penalty.
- Cited as supporting evidence for the open question mTORC1-selective (mTORC2-sparing) dosing captures longevity without insulin resistance.
- Cited as supporting evidence for the open question Brain-penetrant mTOR inhibition clears neurodegenerative aggregates in models but has zero human cognitive-aging endpoint - and mTORC2 is needed for memory.
More studies on this topic
- The Mechanistic Target of Rapamycin: The Grand ConducTOR of Metabolism and Aging (2016)
- Everolimus Aging Study (EVERLAST): Clinical Evaluation of mTORC1 Inhibition for Geroprotection ()
- High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition (2013)
- Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2 (2009)
Learn the biology
Want to understand the biology behind this study? → Feedback Regulation